Fintel reports that on February 19, 2026, Clear Street upgraded their outlook for Korro Bio (NasdaqCM:KRRO) from Hold to Buy.
Analyst Price Forecast Suggests 54.34% Upside
As of February 4, 2026, the average one-year price target for Korro Bio is $17.34/share. The forecasts range from a low of $7.07 to a high of $31.50. The average price target represents an increase of 54.34% from its latest reported closing price of $11.24 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Korro Bio is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.07.
What is the Fund Sentiment?
There are 150 funds or institutions reporting positions in Korro Bio. This is an decrease of 48 owner(s) or 24.24% in the last quarter. Average portfolio weight of all funds dedicated to KRRO is 0.28%, an increase of 23.52%. Total shares owned by institutions decreased in the last three months by 25.66% to 7,941K shares. 
The put/call ratio of KRRO is 1.03, indicating a bearish outlook.
What are Other Shareholders Doing?
Atlas Venture Life Science Advisors holds 1,137K shares representing 12.08% ownership of the company. No change in the last quarter.
NEA Management Company holds 1,091K shares representing 11.58% ownership of the company. No change in the last quarter.
Lynx1 Capital Management holds 678K shares representing 7.20% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Nantahala Capital Management holds 600K shares representing 6.37% ownership of the company.
Qiming U.S. Ventures Management holds 368K shares representing 3.91% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
